AbbVie Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
AbbVie Inc. (ABBV) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2026-08-03
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2026-06-30 was $0.00.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-12-31 was $0.00.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2025-09-30 was $0.00.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2025 was $78.00M.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2024 was $0.00.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- AbbVie Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2022 was $32.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $0.00 10-Q · filed 2026-08-03 | $0.00 derived: sum of 3 quarters · filed 2026-08-03 | $0.00 derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-05-08 | $0.00 derived: sum of 3 quarters · filed 2026-05-08 | $0.00 derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $0.00 derived: sum of 2 quarters · filed 2026-02-20 | $0.00 derived: sum of 3 quarters · filed 2026-08-03 | $78.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2026-08-03 | $78.00M 10-Q · filed 2025-11-04 | $78.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $78.00M 10-Q · filed 2026-08-03 | $78.00M derived: sum of 3 quarters · filed 2026-08-03 | $78.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $78.00M 10-Q · filed 2026-05-08 | $78.00M derived: sum of 2 quarters · filed 2026-05-08 | $78.00M derived: sum of 3 quarters · filed 2026-05-08 | $78.00M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $0.00 derived: sum of 2 quarters · filed 2026-02-20 | $0.00 derived: sum of 3 quarters · filed 2026-02-20 | $0.00 10-K · filed 2026-02-20 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $0.00 10-Q · filed 2025-08-04 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-20 | |||
| 2022-12-31 | $32.00M 10-K · filed 2025-02-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $0.00 derived: sum of 2 quarters · filed 2024-02-20 | $0.00 10-K · filed 2024-02-20 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $0.00 10-Q · filed 2021-11-02 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-02 | |||
| 2020-12-31 | $104.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $104.00M derived: sum of 2 quarters · filed 2023-02-17 | $225.00M 10-K · filed 2023-02-17 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $121.00M 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $121.00M 10-Q · filed 2021-08-02 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $0.00 derived: sum of 2 quarters · filed 2022-02-18 | $0.00 10-K · filed 2022-02-18 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $0.00 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-04 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-19 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $0.00 derived: sum of 2 quarters · filed 2019-02-27 | $0.00 10-K · filed 2019-02-27 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | ||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-07 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$145.00M derived: sum of 2 quarters · filed 2019-02-27 | $3.98B 10-K · filed 2019-02-27 | |
| 2016-09-30 | -$145.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $3.98B 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $4.13B 10-Q · filed 2017-08-07 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | $0.00 derived: sum of 2 quarters · filed 2015-02-20 | $28.00M derived: sum of 3 quarters · filed 2015-02-20 | $28.00M 10-K · filed 2015-02-20 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $28.00M derived: sum of 2 quarters · filed 2014-02-21 | $28.00M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $28.00M 10-K · filed 2014-02-21 | $28.00M 10-Q · filed 2013-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |